Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | USP2 | O75604 | 5/20 | 0.52 |
| ▸ | APAF1 | O14727 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
| ▸ | UBE2N | P61088 | 2/20 | 0.52 |
| ▸ | RAD52 | P43351 | 2/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1775222 | 1.00 | MEN1 (0.60) | MEN1KMT2AUSP2APAF1POLB | |
| SCHEMBL12604821 | 0.99 | MEN1 (0.61) | MEN1KMT2AUSP2APAF1POLB | |
| Iodide SCHEMBL1776111 | 0.90 | MEN1 (0.73) | MEN1KMT2AUSP2APAF1POLB | |
| Iodide SCHEMBL1776114 | 0.90 | MEN1 (0.73) | MEN1KMT2AUSP2APAF1POLB | |
| SCHEMBL12604820 | 0.89 | MEN1 (0.74) | MEN1KMT2AUSP2APAF1POLB | |
| Iodide SCHEMBL1774916 | 0.89 | MEN1 (0.58) | MEN1KMT2AUSP2APAF1POLB | |
| Iodide SCHEMBL1776353 | 0.89 | MEN1 (0.58) | MEN1KMT2AUSP2APAF1POLB | |
| Iodide SCHEMBL1774984 | 0.89 | MEN1 (0.57) | MEN1KMT2AUSP2APAF1POLB | |
| Iodide SCHEMBL1774982 | 0.89 | MEN1 (0.57) | MEN1KMT2AUSP2APAF1POLB | |
| SCHEMBL3682878 | 0.88 | MEN1 (0.59) | MEN1KMT2AUSP2APAF1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943606-B2 | Compositions and methods to control abnormal cell growth | CANCURE LABORATORIES, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100215635-A1 | SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN | KISS ZOLTAN | 2010-08-26 | — | — | US | disclosed |
| US-7781423-B2 | Compounds to promote regeneration of bone marrow | CANCURE LABORATORIES, LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100048668-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100022617-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090317372-A1 | SMALL MOLECULES FOR THE REDUCTION OF HIGH BLOOD GLUCOSE LEVEL | KISS ZOLTAN | 2009-12-24 | — | — | US | disclosed |
| US-7589083-B2 | [3-(3,4-Dimethyl-9-oxo-9H- thioxanthen-2-yloxy)-2- hydroxypropyl]trimethyl- ammonium chloride; antitumor; simultaneously enhancing the efficacy and decreasing the toxicity of chemotherapy by single agents | CANCURE LABORATORIES, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090030066-A1 | SMALL MOLECULES FOR THE PROTECTION OF PANCREATIC CELLS | ZOLTAN LABORATORIES LLC (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090004136-A1 | COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW | ZOLTAN LABORATORIES LLC (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004136-A1 | COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW | PDGFA, BMP4, BMP2 | CHRM1 4598/4885MEN1 3017/4885KMT2A 3032/4885 |
| US-20090317372-A1 | SMALL MOLECULES FOR THE REDUCTION OF HIGH BLOOD GLUCOSE LEVEL | KCNN1, KCNN3, SLC2A9 | CHRM1 2728/4885MEN1 821/4885KMT2A 2305/4885 |
| US-20100215635-A1 | SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN | GPR119, FABP4, PNLIP | CHRM1 3155/4885MEN1 4396/4885KMT2A 1216/4885 |
| US-20100048668-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | ALPP, ALPG, MKI67 | CHRM1 4720/4885MEN1 2734/4885KMT2A 2531/4885 |
| US-20090030066-A1 | SMALL MOLECULES FOR THE PROTECTION OF PANCREATIC CELLS | RNASE1, IAPP, POT1 | CHRM1 2499/4885MEN1 955/4885KMT2A 3699/4885 |
| US-20100022617-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | ALPP, ALPG, DNTT | CHRM1 4758/4885MEN1 3329/4885KMT2A 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.